Scarica l'app Stockscreener
2.13
0.47%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AYTU Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.12
Aprire:
$2.12
Volume 24 ore:
17,097
Relative Volume:
0.01
Capitalizzazione di mercato:
$18.13M
Reddito:
$93.76M
Utile/perdita netta:
$-13.68M
Rapporto P/E:
-0.8099
EPS:
-2.63
Flusso di cassa netto:
$8.77M
1 W Prestazione:
+6.50%
1M Prestazione:
+7.58%
6M Prestazione:
+40.13%
1 anno Prestazione:
-25.52%
Intervallo 1D:
$2.10
$2.16
Intervallo di 1 settimana:
$1.96
$2.17
Portata 52W:
$0.95
$2.96
Aytu Biopharma Inc Stock (AYTU) Company Profile
Nome
Aytu Biopharma Inc
Settore
Telefono
(720) 437-6580
Indirizzo
7900 E. UNION AVENUE, DENVER
Confronta AYTU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.14 | 18.13M | 93.76M | -13.68M | 8.77M | -2.63 |
|
RGC
Regencell Bioscience Holdings Ltd
|
18.55 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
156.26 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.38 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.12 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.82 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Iniziato | H.C. Wainwright | Buy |
Aytu Biopharma Inc Borsa (AYTU) Ultime notizie
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World
Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st
CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance
Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus
Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa
Aytu Biopharma chief business officer buys $24,999 in stock - Investing.com Australia
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com Canada
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia
AYTU BIOPHARMA Executives Increase Stake in Company - TradingView
Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - ACCESS Newswire
Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan
Aytu BioPharma to commercialise Exxua for MDD in the US - Yahoo Finance
Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug - Investing.com
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News - GuruFocus
AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News - GuruFocus
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States | AYTU - GuruFocus
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - ACCESS Newswire
Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization - Stock Titan
New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News - Stock Titan
AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Growth in Short Interest - Defense World
Aytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32% - MSN
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
Aytu BioPharma Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus
Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com India
Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView
Transcript : Aytu BioPharma, Inc., Q3 2025 Earnings Call, May 14, 2025 - marketscreener.com
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire
Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aytu Biopharma Inc Azioni (AYTU) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
| Disbrow Joshua R. | Chief Executive Officer |
Feb 28 '25 |
Buy |
1.30 |
15,000 |
19,500 |
86,591 |
0.28%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):